PA
MGM icon

PharVision Advisers’s MGM Resorts International MGM Stock Holding History

PharVision Advisers’s Portfolio MGM Stock Details MGM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-6,125
Closed -$212K – 422
2024
Q4 		$212K Buy
+6,125
New +$232K 0.18% 276

Other funds holding MGM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DSA
Davis Selected Advisers Tucson, Arizona $21.8B AUM 23.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
CM
Corvex Management New York $2.52B AUM 25.53% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

PharVision Advisers's MGM Position: Q1 2025 in Review

PharVision Advisers sold out of MGM Resorts International (MGM) in Q1 2025, closing a stake of 6,125 shares — an estimated $212K sold.

PharVision Advisers first reported a position in MGM in Q4 2024 and held it in 1 quarter. The position peaked at $212K in Q4 2024. 621 funds tracked by Wall St. Rank hold MGM as of Q1 2025.

  • PharVision Advisers reported no remaining MGM Resorts International position as of Q1 2025 after selling out during the quarter.
  • PharVision Advisers sold 6,125 MGM Resorts International shares in Q1 2025, an estimated $212K.
  • PharVision Advisers first reported a position in MGM Resorts International in Q4 2024 and held it in 1 quarter.
  • PharVision Advisers's MGM Resorts International position peaked at $212K in Q4 2024.
  • 621 funds tracked by Wall St. Rank held MGM Resorts International as of Q1 2025.

Based on PharVision Advisers's 13F filing for Q1 2025, filed 15 May 2025.